The global COVID-19 pandemic has disrupted every aspect of the healthcare system. Apart
from the issues surrounding COVID-19 itself, care for existing patients has met many …

DISCUSSION We have highlighted an important clinical lesson in this case. Benign
clozapine-associated eosinophilia without systemic inflammation can be followed by a safe …

We report five cases of treatment-resistant schizophrenia that presented with prominent
negative and positive symptoms. They fulfill the criteria of diagnosis of schizophrenia …

The current study aimed to assess the possibility of an association between first and second
generation antipsychotic medication and raised eosinophil count. A total of 22 in‑patients at …

Background Although clozapine is much researched in western literature, a review on Indian
research on clozapine published in 2010 reported limited data and need for further research …

Schizophrenia is a chronic neuropsychiatric illness defined by the appearance of positive,
and negative symptoms and/or cognitive impairment. Antipsychotic drugs are predominantly …

目前精神分裂症(SZ) 的治疗仍以药物治疗为主, 其中约30% 的患者属于难治性SZ.
现有药物中氯氮平仍然是难治性SZ 的首选. 作为首选药物, 氯氮平疗效确切的同时 …

To the Editors: Clozapine is an atypical antipsychotic indicated for treatment resistant
schizophrenia. Common adverse effects include drowsiness, sialorrhea, weight gain, and …

Clozapine is the only approved antipsychotic for treatment-resistant schizophrenia, which is
its main use. It is also approved in many countries for the treatment of psychotic symptoms in …

Pharmaceutical therapy is still the primary treatment for schizophrenia. For refractory
schizophrenia, which affects about 30% of the patients with schizophrenia, clozapine is a …